The Kinghorn Cancer Centre, St Vincent's Health Network Sydney
Welcome,         Profile    Billing    Logout  
 72 Trials 
126 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GREILLIER, Laurent
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

Recruiting
4
500
Europe
Bio-bank repository, Quality of Life (QoL), G-Code
Groupe Francais De Pneumo-Cancerologie
Non Small Cell Lung Cancer, Lung Cancer
08/26
08/28
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Active, not recruiting
3
500
Europe
Carboplatin, Paclitaxel, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
12/24
12/26
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

Active, not recruiting
3
349
Europe
Pembrolizumab, Pembrolizumab and Chemotherapy drugs
University Hospital, Brest, Groupe Français de Pneumo-Cancérologie
Non-small-cell Lung Cancer
12/25
12/25
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
560
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
NCT05027867 / 2021-001530-19: KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Terminated
2
3
Europe, US, RoW
KRT-232, navtemadlin
Kartos Therapeutics, Inc.
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
08/22
08/22
PECATI, NCT04710628: Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

Active, not recruiting
2
43
Europe
Pembrolizumab, MK-3475, lambrolizumab, Lenvatinib 10 mg, E7080
MedSIR, Merck Sharp & Dohme LLC
Metastatic Thymic Carcinoma, Thymoma Type B3
07/24
01/26
NIVOTHYM, NCT03134118 / 2015-005504-28: Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma

Active, not recruiting
2
55
Europe
Nivolumab, BMS-936558-01
European Organisation for Research and Treatment of Cancer - EORTC, ETOP IBCSG Partners Foundation
Thymoma Type B3, Thymic Carcinoma
12/23
07/24
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer

Active, not recruiting
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
01/25
01/25
FIRST-NEC, NCT06393816: (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Recruiting
2
80
Europe, RoW
Durvalumab with etoposide and Carboplatin/Cisplatin, MEDI4736
Centre Leon Berard, Groupe Français de Pneumo-Cancérologie
Large Cell Neuroendocrine Carcinoma of the Lung
09/28
09/29
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

Not yet recruiting
2
30
Europe
Repotrectinib
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon
NSCLC Stage IV, NSCLC, Stage III
09/31
09/31
SPORADIC, NCT06656598: Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer

Not yet recruiting
2
152
Europe
Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance)
Intergroupe Francophone de Cancerologie Thoracique
Stage III NSCLC
09/28
01/32
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Recruiting
2
186
Europe, Canada, US, RoW
inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta
iTeos Therapeutics, iTeos Belgium SA
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
04/25
05/25
MATISSE, NCT05742607 / 2022-001903-42: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer

Recruiting
2
70
Europe, US
IPH5201 + durvalumab + standard chemotherapy, Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy
Innate Pharma, Innate Pharma SA
Non Small Cell Lung Cancer
06/25
09/26
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

Active, not recruiting
2
156
Europe
Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer
09/25
06/26
ADEPPT, NCT05673187 / 2022-002736-31: Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

Recruiting
2
68
Europe
Adagrasib
ETOP IBCSG Partners Foundation, Mirati Therapeutics Inc.
NSCLC Stage IV, KRAS P.G12C
10/25
03/26
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)

Recruiting
2
67
Europe
Carboplatin + Paclitaxel + Durvalumab
Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer Extensive Stage
02/26
02/28
DURVALUNG, NCT05617963 / 2021-005920-39: Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

Recruiting
2
550
Europe
Durvalumab
UNICANCER, AstraZeneca
Small Cell Lung Carcinoma
01/27
03/29
BOUNCE, NCT05718297: Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Withdrawn
2
44
Europe
Brigatinib, Durvalumab
ETOP IBCSG Partners Foundation, Takeda
NSCLC, Stage III, ALK-rearrangement
09/24
09/24
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, not recruiting
1/2
61
Europe, Japan, US, RoW
M1774, Tuvusertib, Cemiplimab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-Small Cell Lung Cancer
05/25
02/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting
1
180
Europe, US, RoW
IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan
IDEAYA Biosciences
Solid Tumor
12/26
03/27
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting
1
198
Europe, US, RoW
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1
Enliven Therapeutics
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
07/26
07/26
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

Active, not recruiting
N/A
420
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/27
05/27
MESO-IMMUNE, NCT05308966: Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab

Active, not recruiting
N/A
200
Europe
Data collection
Groupe Francais De Pneumo-Cancerologie, Bristol-Myers Squibb
Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm
04/25
04/25
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
REAL-MOOV-LUNG, NCT04934865: Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients :

Active, not recruiting
N/A
240
Europe
Patients treated for their lung cancer.
Institut Curie
Lung Cancer
10/26
10/26
OBSTINATE, NCT05049044: Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC

Active, not recruiting
N/A
413
Europe
Quality of Life Questionnaire-Core 30 (QLQ-C30), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), 5-level EuroQoL EQ5D (EQ5D-5L)
Groupe Francais De Pneumo-Cancerologie, AstraZeneca
Non-Small Cell Lung Cancer
06/27
06/27
Italiano, Antoine
CRYOMUNE, NCT04339218: Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma

Recruiting
3
214
Europe
Cryoablation, Pembrolizumab, Pemetrexed, Carboplatin
Institut Bergonié
Lung Adenocarcinoma, Cryotherapy Effect
08/26
08/28
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
FIBROSARC, NCT04650984 / 2016-003239-38: A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Recruiting
3
102
Europe
Onfekafusp alfa, L19TNF, Doxorubicin
Philogen S.p.A.
Soft Tissue Sarcoma
12/25
12/25
TANGENT, NCT05417789: Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

Recruiting
3
128
Europe, Canada, US, RoW
Emactuzumab, Placebo
SynOx Therapeutics Limited
TGCT
04/26
09/27
MOTION, NCT05059262 / 2020-004883-25: Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Active, not recruiting
3
120
Europe, Canada, US, RoW
vimseltinib, DCC-3014, Placebo
Deciphera Pharmaceuticals LLC, Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
08/23
07/26
CIRSARC, NCT03805022 / 2018-000186-36: Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

Recruiting
3
351
Europe
Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator
Institut Bergonié, Novartis, Chugai Pharma France
Non-metastatic Soft-tissue Sarcoma, Resectable
02/25
02/25
RAR-Immune, NCT04741438: Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Recruiting
3
96
Europe
Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient]
Centre Leon Berard
Sarcoma
02/25
08/25
CHIC-STS01, NCT04307277 / 2019-003014-13: Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma

Recruiting
3
600
Europe
Standard of care + chemotherapy, Standard of care
Institut Claudius Regaud, Direction Générale de l’Offre de Soins (DGOS)
Soft Tissue Sarcoma
10/32
10/32
ImadGist, NCT02260505 / 2013-001372-37: Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)

Completed
3
136
Europe
Imatinib maintenance, Glivec, Imatinib mésilate
Centre Leon Berard, INCA
Gastrointestinal Stromal Tumors, Resected Gastrointestinal Stromal Tumors, Non-metastatic, High Risk of Recurrence, KIT Gene Mutation
12/23
12/23
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
06/24
NCT01267955: Vismodegib in Treating Patients With Advanced Chondrosarcomas

Active, not recruiting
2
45
Europe
Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Vismodegib, Erivedge, GDC 0449, GDC-0449, GDC0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma, Locally Advanced Chondrosarcoma, Mesenchymal Chondrosarcoma, Metastatic Chondrosarcoma, Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
06/18
07/25
NCT02243605: Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Checkmark Data from CABONE trial in advanced Ewing sarcoma or osteosarcoma
Feb 2020 - Feb 2020: Data from CABONE trial in advanced Ewing sarcoma or osteosarcoma
Active, not recruiting
2
90
Europe
Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Metastatic Ewing Sarcoma, Metastatic Osteosarcoma, Recurrent Ewing Sarcoma, Recurrent Osteosarcoma, Stage III Osteosarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Unresectable Ewing Sarcoma, Unresectable Osteosarcoma
06/19
07/25
PEMBROSARC, NCT02406781: Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial

Active, not recruiting
2
227
Europe
Combination of MK3475 with Metronomic CP, Pembrolizumab, Endoxan, Combination of MK3475 with Metronomic CP and G100, Pembrolizumab, Endoxan, GLA-SE (glucopyranosyl lipid adjuvant-stable emulsion).
Institut Bergonié, Merck Sharp & Dohme LLC, Ministry of Health, France, Immune Design
Sarcoma
11/20
08/21
REGISTRI, NCT02638766 / 2015-001048-12: Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST

Completed
2
15
Europe
regorafenib, Stivarga
Grupo Espanol de Investigacion en Sarcomas, Bayer
Gastrointestinal Stromal Tumors
08/21
08/21
GUIDE2REPAIR, NCT04169841: Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

Active, not recruiting
2
270
Europe
olaparib, durvalumab, tremelimumab
Centre Georges Francois Leclerc, AstraZeneca
Immunotherapy
08/27
08/27
CAIRE, NCT04705818 / 2019-003303-35: Combining Epigenetic And Immune Therapy to Beat Cancer.

Recruiting
2
173
Europe
Durvalumab, Tazemetostat
Institut Bergonié, AstraZeneca, Epizyme, Inc.
Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma, Adult Solid Tumor
07/23
01/25
LENVAGIST, NCT04193553: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

Completed
2
77
Europe
Lenvatinib, Placebo, Best supportive care
Centre Leon Berard
Gastro Intestinal Stromal Tumour
01/24
04/24
FLASH, NCT04733183 / 2018-004104-19: Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

Active, not recruiting
2
98
Europe
Dacarbazine, DTIC, onfekafusp alfa, L19TNF
Philogen S.p.A., Philogen S.p.A.,
Soft Tissue Sarcoma
12/25
12/25
EREMISS, NCT03793361: Phase II Study of Regorafenib as Maintenance Therapy

Completed
2
127
Europe
Regorafenib, stivarga, Placebo
Centre Oscar Lambret
Metastatic Soft Tissue Sarcoma
03/24
09/24
CONGRATS, NCT04095208 / 2019-002332-81: Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study

Recruiting
2
67
Europe
Association of Nivolumab + Relatlimab, Nivolumab
Institut Bergonié, Bristol-Myers Squibb
Soft Tissue Sarcoma Adult, Advanced Cancer
06/24
12/25
AGADIR, NCT03915678 / 2019-000850-78: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Recruiting
2
247
Europe
Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT
Institut Bergonié, Roche Pharma AG, National Cancer Institute, France, Eikon Therapeutics
Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer
09/24
03/26
TRUST, NCT04874311 / 2020-005703-39: Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Recruiting
2
80
Europe
Bintrafusp alfa, Doxorubicin
Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
09/24
03/25
TARSARC, NCT04807816 / 2018-003835-31: Targeting ATR in Soft-tissue Sarcomas

Recruiting
2
72
Europe
Association of berzosertib with gemcitabine, Experimental, Gemcitabine, Control
Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Leiomyosarcoma, Adult
10/24
04/26
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc., Bristol-Myers Squibb
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
12/25
12/28
MOST plus, NCT02029001: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

Recruiting
2
900
Europe
Nilotinib (400 mg BID), Open cohort, Everolimus (10 mg QD), Closed cohort, Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD), Olaparib (300 mg BID), Durvalumab + Tremelimumab
Centre Leon Berard, National Cancer Institute, France
Malignant Solid Neoplasms
01/26
10/27
GIST-TEN, NCT05009927: Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

Recruiting
2
50
Europe
Imatinib tablets, Glivec
Centre Leon Berard
Metastatic Gastrointestinal Stromal Tumor (GIST), C-KIT Mutation, Advanced Gastrointestinal Stromal Tumor (GIST)
01/25
01/27
ATEZOGIST, NCT05152472: A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

Recruiting
2
110
Europe
Atezolizumab 1200 mg, Tecentriq®, Imatinib 400 MG, Glivec®
Centre Leon Berard
Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
10/27
10/27
TORNADO, NCT04968106: Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas

Recruiting
2
66
Europe
Doxorubicin, Ifosfamide, INCMGA00012, Retifanlimab
Institut Bergonié, Incyte Biosciences International Sàrl
Resectable Sarcoma
03/25
10/27
NCT05503797 / 2022-000627-20: A Study to Assess the Efficacy and Safety of FORE8394 in Participants with Cancer Harboring BRAF Alterations

Recruiting
2
250
Europe, Canada, US, RoW
Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R)
Fore Biotherapeutics, Fore Biotherapeutics
Cancer Harboring BRAF Alterations
06/25
08/26
REGOBONE, NCT02389244 / 2013-003910-42: A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

Checkmark Data from REGOBONE trial for relapsed advanced or metastatic chordoma at ESMO 2021
Jul 2021 - Jul 2021: Data from REGOBONE trial for relapsed advanced or metastatic chordoma at ESMO 2021
Active, not recruiting
2
163
Europe
Regorafenib, Stivarga, Placebo, Placebo tablet
UNICANCER
Ewing Sarcomas, Chondrosarcomas, Osteosarcomas, Chondroma, CIC-Rearranged Sarcoma
10/24
06/25
EXOMA2, NCT04614480: Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine

Recruiting
2
2518
Europe
Exome analysis
Centre Georges Francois Leclerc
Cancer
09/25
09/29
MegaMOST, NCT04116541: A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors.

Recruiting
2
455
Europe
HDM201, Closed cohort, Ribociclib, Cabozantinib, Open cohort, Alectinib, Regorafenib, Trametinib, Dabrafenib, Avapritinib
Centre Leon Berard
Malignant Solid Tumor
02/26
11/26
TAYLOR, NCT05888857: MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.

Not yet recruiting
2
102
Europe
MEDI5752
Institut Bergonié, National Cancer Institute, France, AstraZeneca
Advanced Solid Tumor
03/26
09/27
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/27
05/27
EMPIRE, NCT06084689: Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

Not yet recruiting
2
120
Europe
Ezabenlimab + BI907828
Institut Bergonié, Boehringer Ingelheim
Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Biliary Tract Cancer
07/26
01/27
NCT05440786 / 2021-004734-11: CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Recruiting
2
45
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Sarcoma, Ewing, Neoplasm Metastasis
02/27
09/28
NCT05920408 / 2022-001385-35: Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours

Terminated
1b/2a
6
Europe
EXS21546
Exscientia AI Limited, Biotrial
Advanced Solid Tumours
09/23
10/23
METROmaJX, NCT02630368: A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma

Checkmark Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Sep 2018 - Sep 2018: Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Recruiting
1/2
197
Europe
Cyclophosphamide and JX-594 dose escalation, Brand name : ENDOXAN, Brand name: Pexa-Vec, Cyclophosphamide and JX-594, Cyclophosphamide, Avelumab and JX-594 and Cyclophosphamide, Brand name: ENDOXAN, Brand name: Avelumab
Institut Bergonié, National Cancer Institute, France, Fondation ARC, Merck Sharp & Dohme LLC, Transgene
Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
05/23
11/24
NCT03568656 / 2018-000285-10: Study to Evaluate CCS1477 in Advanced Tumours

Recruiting
1/2
350
Europe, US
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
CellCentric Ltd.
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
12/24
12/24
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
INJECTABL-1, NCT05688280 / 2022-000176-19: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Active, not recruiting
1/2
42
Europe, US
1.0% IP-001 for Injection, IP-001
Immunophotonics, Inc., Immunophotonics Inc.
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
02/25
02/25
REGOMUNE, NCT03475953 / 2016-005175-27: A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Recruiting
1/2
747
Europe
Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib, Phase 2 : Avelumab, Phase 2: low-dose Regorafenib
Institut Bergonié, Bayer, Merck KGaA, Darmstadt, Germany
Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer, Hepatocellular Carcinoma, Soft-tissue Sarcoma, Thyroid Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Non-small Cell Lung Cancer, Solid Tumor, Adult, Urothelial Carcinoma, HPV-Related Carcinoma, Triple Negative Breast Cancer, Renal Carcinoma, Mesotheliomas Pleural
12/24
12/25
AMPHISARC, NCT05180695: HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

Recruiting
1/2
58
Europe
Pazopanib, Votrient, HDM201, siremadlin
Centre Leon Berard, Novartis, National Cancer Institute, France
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
01/26
07/26
TNG908-C101, NCT05275478 / 2021-005605-27: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Active, not recruiting
1/2
192
Europe, US
TNG908
Tango Therapeutics, Inc., Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
04/25
09/25
Duravelo-1, NCT04561362 / 2020-002719-23: Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Recruiting
1/2
329
Europe, Canada, US
BT8009, Pembrolizumab, Keytruda
BicycleTx Limited
Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
12/26
12/26
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
03/26
07/26
SPARTO, NCT05210413: Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults

Recruiting
1/2
59
Europe
Spartalizumab in Pediatric cohort, Low-dose Pazopanib in Pediatric Cohort, Spartalizumab in Adult cohort, Low-dose Pazopanib in Adult Cohort
University Hospital, Bordeaux, National Cancer Institute, France, Fondation ARC, Novartis
Refractory or Recurrent Solid Tumor
11/26
11/27
START-001, NCT05592626: A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors

Recruiting
1/2
365
Europe, Canada, US
STAR0602
Marengo Therapeutics, Inc.
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm
10/26
10/26
EP0031-101, NCT05443126: A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting
1/2
265
Europe, US, RoW
EP0031
Ellipses Pharma
Advanced Solid Tumor
12/26
06/27
TRASTS, NCT02275286: Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

Recruiting
1/2
199
Europe
Trabectedin, Yondelis, Radiotherapy
Grupo Espanol de Investigacion en Sarcomas, Centre Leon Berard, Italian Sarcoma Group
Liposarcoma, Myxoid, Sarcoma, Soft Tissue, Leiomyosarcoma, Liposarcoma, Pleomorphic Liposarcoma
06/28
06/28
NCT03990233: A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Checkmark From trial in combination with BI 754091 for solid tumors
Jun 2021 - Jun 2021: From trial in combination with BI 754091 for solid tumors
Active, not recruiting
1
116
Europe
BI 765063, OSE-172, BI 754091
OSE Immunotherapeutics, Boehringer Ingelheim
Solid Tumor, Adult
04/23
12/25
IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting
1
180
Europe, US, RoW
IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan
IDEAYA Biosciences
Solid Tumor
12/26
03/27
NCT04241835: A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Recruiting
1
24
Europe, US
Tazemetostat, EPZ-6438, IPN60200, Tazverik®
Epizyme, Inc., Sponsor GmbH
Hepatic Impairment, Advanced Malignant Solid Tumor
05/25
06/25
NCT03843359: A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Active, not recruiting
1
97
Europe, Canada, Japan, US, RoW
GSK3745417, Dostarlimab
GlaxoSmithKline
Neoplasms
04/24
03/25
NCT04901806 / 2021-001029-32: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Terminated
1
28
Europe, RoW
BBP-398, sotorasib
Navire Pharma Inc., a BridgeBio company, Amgen
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
08/24
08/24
NCT06551142: A Study of GSK5764227 in Participants With. Advanced Solid Tumors

Recruiting
1
240
Canada, Japan, US, RoW
GSK5764227, Cisplatin, Carboplatin, Atezolizumab, Pembrolizumab, Durvalumab, Fluorouracil, Folinic acid, Cetuximab, Bevacizumab
GlaxoSmithKline
Neoplasms
07/26
03/27
PEMBIB, NCT02856425: Trial Of Pembrolizumab And Nintedanib

Recruiting
1
221
Europe
Nintedanib, Pembrolizumab
Gustave Roussy, Cancer Campus, Grand Paris
Patients With Any Advanced Solid Tumors
11/25
11/28
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
STING, NCT04932525: Gustave Roussy Cancer Profiling

Recruiting
1
10000
Europe
Biopsy
Gustave Roussy, Cancer Campus, Grand Paris
Solid Tumor, Unspecified, Adult
05/28
05/28
ETIOSARC, NCT03670927: Etiosarc: Environmental Aetiology of Sarcomas From a Multicenter French Population-based Case-control Study Among Adults

Completed
N/A
2237
Europe
Environmental, occupational and lifestyle-related exposures
Institut National de la Santé Et de la Recherche Médicale, France
Sarcoma, Environmental Exposure, Occupational Exposure, Life Style
07/24
07/24
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing
N/A
Europe, Japan, US, RoW
Selpercatinib, LOXO-292, LY3527723
Eli Lilly and Company, Eli Lilly and Company
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
 
 
PIPER, NCT04008238: Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients

Recruiting
N/A
200
Europe
Trabectedin
Institut Bergonié
Soft Tissue Sarcoma Adult, Undifferentiated Pleomorphic Sarcoma, Epithelioid Sarcoma, Solitary Fibrous Tumors, Hemangioendothelioma, Desmoplastic Round Cell Tumor, Synovial Sarcoma
01/24
01/25
COPE, NCT04258137: Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study

Recruiting
N/A
332
Europe
Liquid biopsy
Institut Bergonié
Colorectal Cancer, Non Small Cell Lung Cancer
09/24
04/25
NEOSarcomics, NCT02789384: CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.

Recruiting
N/A
205
Europe
Procedure/Surgery
Institut Bergonié, National Cancer Institute, France, Ministry of Health, France
Soft-tissue Sarcomas
01/25
08/27
TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting
N/A
500
Europe, RoW
Data collection and quality of life questionnaire
Centre Leon Berard
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation
06/25
06/25
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
REGOSTA, NCT04055220 / 2018-004045-16: Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

Recruiting
N/A
168
Europe
Treatment by Regorafenib, Stivarga, Treatment by Placebo, Standard of care
Centre Leon Berard
Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Angiosarcoma
10/26
10/26
BIP, NCT02534649: Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

Recruiting
N/A
10000
Europe
Newly obtained biopsy and Blood samples collection
Institut Bergonié
Solid Tumor, Hematological Malignancy
03/28
12/29
OPTISARC, NCT05272358: Economic Evaluation of Sarcoma Patients Management in France

Recruiting
N/A
2431
Europe
NETSARC network
Centre Leon Berard, École nationale supérieure des Mines Saint-Etienne France, Rennes University Hospital, Assistance Publique - Hôpitaux de Paris
Sarcoma
06/22
02/24
 

Download Options